Background: Rituximab (RTX) is the most commonly used biologic for the treatment of SLE. However, there is are no clinically applicable predictors of response, which is of particular importance in this heterogeneous disease with other biologics being restricted to certain subgroups. Objectives: To assess factors associated with primary and secondary nonresponse to RTX in SLE in order to develop more targeted and effective B-cell therapy. Methods: A prospective observational study was conducted in 125 SLE patients treated with RTX in Leeds for over 12 years. A major clinical response was defined as improvement of all active BILAG-2004 domains to grade C/better and no A/B flare. Partial responders were defined by 1 persistent BILAG B. B-cell subsets were measured using highly sensitive flow cytometry. Predictors of response were analysed using logistic regression analysis.
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